KALARIS THERAPEUTICS, INC. Stock-Based Compensation
KALARIS THERAPEUTICS, INC. (KLRS) reported Stock-Based Compensation of $1.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $644.00K, a 8.97% increase year-over-year.
- KALARIS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $580.00K, a 55.08% increase year-over-year.
- KALARIS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $333.00K, a 18.93% increase year-over-year.
- KALARIS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $638.00K, a 143.51% increase year-over-year.
- KALARIS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $1.94M, a 116.31% increase from fiscal 2024.
- KALARIS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $895.00K, a 97.81% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $40.78M, a 1.30% decline from fiscal 2022.
- KALARIS THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $41.31M, a 6.05% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $644.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.22M 10-Q · filed 2026-08-11 | $1.56M derived: sum of 3 quarters · filed 2026-08-11 | $2.19M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $580.00K 10-Q · filed 2026-05-12 | $913.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.55M derived: sum of 3 quarters · filed 2026-05-12 | $2.14M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $971.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.56M derived: sum of 3 quarters · filed 2026-08-11 | $1.94M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $638.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.23M derived: sum of 2 quarters · filed 2026-08-11 | $1.60M 10-Q · filed 2025-11-12 | $1.88M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $591.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $965.00K 10-Q · filed 2026-08-11 | $1.25M derived: sum of 3 quarters · filed 2026-08-11 | $1.51M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $374.00K 10-Q · filed 2026-05-12 | $654.00K derived: sum of 2 quarters · filed 2026-05-12 | $916.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.24M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $280.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $542.00K derived: sum of 2 quarters · filed 2026-03-17 | $864.00K derived: sum of 3 quarters · filed 2026-03-17 | $895.00K 10-K · filed 2026-03-17 | $26.35M 10-K · filed 2025-03-07 | |||
| 2024-09-30 | $262.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $584.00K derived: sum of 2 quarters · filed 2025-11-12 | $615.00K 10-Q · filed 2025-11-12 | $15.89M 10-Q · filed 2024-11-12 | $10.61M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $322.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $353.00K 10-Q · filed 2025-08-13 | $10.94M 10-Q · filed 2024-08-09 | $10.35M derived: sum of 3 quarters · filed 2025-08-13 | $20.82M derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $31.00K 10-Q · filed 2025-05-14 | $5.03M 10-Q · filed 2024-05-13 | $10.03M derived: sum of 2 quarters · filed 2025-05-14 | $20.49M derived: sum of 3 quarters · filed 2025-05-14 | $30.78M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $9.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $20.46M derived: sum of 2 quarters · filed 2025-03-07 | $30.75M derived: sum of 3 quarters · filed 2025-03-07 | $40.78M 10-K · filed 2025-03-07 | ||||
| 2023-09-30 | $10.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $20.76M derived: sum of 2 quarters · filed 2024-11-12 | $30.79M 10-Q · filed 2024-11-12 | $39.83M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $10.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $20.32M 10-Q · filed 2024-08-09 | $29.36M derived: sum of 3 quarters · filed 2024-08-09 | $40.21M derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | $10.03M 10-Q · filed 2024-05-13 | $19.07M derived: sum of 2 quarters · filed 2024-05-13 | $29.93M derived: sum of 3 quarters · filed 2024-05-13 | $40.88M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $9.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $19.90M derived: sum of 2 quarters · filed 2024-03-15 | $30.85M derived: sum of 3 quarters · filed 2024-03-15 | $41.31M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $10.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $21.81M derived: sum of 2 quarters · filed 2023-11-02 | $32.27M 10-Q · filed 2023-11-02 | $48.13M derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | $10.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $21.42M 10-Q · filed 2023-08-03 | $37.28M derived: sum of 3 quarters · filed 2023-08-03 | $47.56M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | $10.47M 10-Q · filed 2023-05-04 | $26.33M derived: sum of 2 quarters · filed 2023-05-04 | $36.61M derived: sum of 3 quarters · filed 2023-05-04 | $46.34M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $15.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $26.15M derived: sum of 2 quarters · filed 2023-02-15 | $35.87M derived: sum of 3 quarters · filed 2023-02-15 | $43.98M 10-K · filed 2023-02-15 | ||||
| 2021-09-30 | $10.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $20.01M derived: sum of 2 quarters · filed 2022-11-03 | $28.11M 10-Q · filed 2022-11-03 | $32.55M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | $9.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $17.83M 10-Q · filed 2022-08-04 | $22.26M derived: sum of 3 quarters · filed 2022-08-04 | $26.12M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $8.10M 10-Q · filed 2022-05-05 | $12.53M derived: sum of 2 quarters · filed 2022-05-05 | $16.39M derived: sum of 3 quarters · filed 2022-05-05 | $16.89M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $8.29M derived: sum of 2 quarters · filed 2022-02-10 | $8.78M derived: sum of 3 quarters · filed 2022-02-10 | $9.43M 10-K · filed 2022-02-10 | ||||
| 2020-09-30 | $3.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $4.35M derived: sum of 2 quarters · filed 2021-11-05 | $5.00M 10-Q · filed 2021-11-05 | $5.62M derived: sum of 4 quarters · filed 2021-11-05 | ||||
| 2020-06-30 | $492.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $1.14M 10-Q · filed 2021-08-06 | $1.76M derived: sum of 3 quarters · filed 2021-08-06 | $2.36M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $646.00K 10-Q · filed 2021-05-06 | $1.27M derived: sum of 2 quarters · filed 2021-05-06 | $1.86M derived: sum of 3 quarters · filed 2021-05-06 | |||||
| 2019-12-31 | $622.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $1.22M derived: sum of 2 quarters · filed 2021-02-12 | $2.89M 10-K · filed 2021-02-12 | |||||
| 2019-09-30 | $596.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $2.27M 10-Q · filed 2020-11-10 | ||||||
| 2019-06-30 | $1.67M 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |